Market Price

Price is unknown


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-126 that is in Phase 2b clinical trial; DE-128, which is in Phase 2/3 clinical trial; DE-130A that is in Phase III clinical trial; and DE-117. In addition, the company provides DE-114A to treat allergic conjunctivitis that has completed phase 3 clinical trial; DE-076C for the treatment of Vernal keratoconjunctivitis; DE-109, which is in Phase 3 clinical trial to treat uveitis; and DE-122 that is in Phase 2a clinical trial for the treatment of wet age-related macular degeneration. Further, it intends to initiate Phase 2/3 clinical trial for DE-127 to treat myopia; and MD-16 for the treatment of cataract that has completed Phase III clinical trial. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Mar '12 Dec '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20
Equity (BVPS) 11.23
3.39
12.97
3.16
3.05
3.64
4.90
5.22
5.22
5.99
6.35
growth rate -69.8% 282.6% -75.6% -3.5% 19.3% 34.6% 6.5% 0.0% 14.8% 6.0%
Earnings BIT 202.87
186.81
27,315.00
35,240.00
36,330.00
32,904.00
38,802.00
41,390.00
39,860.00
growth rate -4.0% 14,522.0% 29.0% 3.1% -9.4% 17.9% 6.7% -3.7%
Avg.PE 17.86
22.03
21.46
13.53
13.53
24.47
17.82
17.36
20.92
growth rate 11.1% -2.6% -37.0% 0.0% 80.9% -27.2% -2.6% 20.5%
ROA 6.58
8.95
11.78
8.29
7.94
8.98
16.18
6.80
9.92
8.19
5.90
growth rate 36.0% 31.6% -29.6% -4.2% 13.1% 80.2% -58.0% 45.9% -17.4% -28.0%
ROE 8.02
10.68
14.24
10.01
9.88
12.23
22.63
8.99
13.09
11.08
7.96
growth rate 33.2% 33.3% -29.7% -1.3% 23.8% 85.0% -60.3% 45.6% -15.4% -28.2%
ROIC 7.87
10.65
14.19
9.98
9.85
12.06
22.83
9.17
12.90
11.59
8.28
growth rate 35.3% 33.2% -29.7% -1.3% 22.4% 89.3% -59.8% 40.7% -10.2% -28.6%
Cur. Ratio 4.50
5.12
4.70
4.91
3.99
2.67
2.66
2.94
2.94
3.21
3.23
growth rate 13.8% -8.2% 4.5% -18.7% -33.1% -0.4% 10.5% 0.0% 9.2% 0.6%
Quick Ratio 3.77
4.26
3.99
3.91
3.29
2.27
2.27
2.33
2.39
2.57
2.65
growth rate 13.0% -6.3% -2.0% -15.9% -31.0% 0.0% 2.6% 2.6% 7.5% 3.1%
Leverage 1.20
1.21
1.21
1.21
1.28
1.44
1.37
1.28
1.36
1.34
1.35
growth rate 0.8% 0.0% 0.0% 5.8% 12.5% -4.9% -6.6% 6.3% -1.5% 0.8%
Balance Sheet Dec '11 Mar '12 Dec '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20
Acct.Receivable 37,922.00
43,839.00
52,083.00
61,701.00
65,998.00
70,970.00
78,654.00
84,618.00
86,999.00
growth rate 7.5% 18.8% 18.5% 7.0% 7.5% 10.8% 7.6% 2.8%
Acct.Payable 9,266.00
14,270.00
20,250.00
24,504.00
23,937.00
29,743.00
32,079.00
32,578.00
growth rate 54.0% 41.9% 21.0% -2.3% 24.3% 7.9% 1.6%
Cur.Assets 996.04
132,582.00
156,006.00
150,672.00
194,739.00
157,011.00
183,367.00
194,742.00
218,556.00
growth rate 1,053.7% 17.7% -3.4% 29.3% -19.4% 16.8% 6.2% 12.2%
Total Assets 1,451.25
199,640.00
231,105.00
304,200.00
355,399.00
322,778.00
388,463.00
391,186.00
408,768.00
growth rate 1,072.9% 15.8% 31.6% 16.8% -9.2% 20.4% 0.7% 4.5%
Cash 483.52
50,884.00
63,509.00
65,923.00
99,798.00
53,297.00
69,283.00
70,796.00
91,430.00
growth rate 925.9% 24.8% 3.8% 51.4% -46.6% 30.0% 2.2% 29.2%
Inventory 127.44
20,947.00
20,030.00
20,133.00
24,996.00
28,502.00
30,636.00
35,235.00
35,282.00
growth rate 1,182.1% -4.4% 0.5% 24.2% 14.0% 7.5% 15.0% 0.1%
Cur.Liabilities 194.72
27,011.00
39,093.00
56,340.00
73,230.00
53,434.00
62,201.00
60,663.00
67,597.00
growth rate 1,077.8% 44.7% 44.1% 30.0% -27.0% 16.4% -2.5% 11.4%
Liabilities 247.76
34,508.00
49,897.00
92,421.00
95,390.00
68,894.00
100,906.00
98,614.00
106,208.00
growth rate 1,080.2% 44.6% 85.2% 3.2% -27.8% 46.5% -2.3% 7.7%
LT Debt 0.84
0.64
25,304.00
25,304.00
12,914.00
7,598.00
3,500.00
3,563.00
1,965.00
growth rate -13.0% 3,984,154.5% 0.0% -49.0% -41.2% -53.9% 1.8% -44.9%
Equity 1,203.49
1,205.46
181,208.00
211,779.00
260,009.00
253,065.00
285,823.00
290,900.00
302,865.00
growth rate 0.1% 14,932.2% 16.9% 22.8% -2.7% 12.9% 1.8% 4.1%
Common Shares 85.00
436.00
85.00
422.00
414.00
415.00
416.00
412.00
408.00
407.00
400.00
growth rate 412.9% -80.5% 396.5% -1.9% 0.2% 0.2% -1.0% -1.0% -0.3% -1.7%
Cash Flow Statement Dec '11 Mar '12 Dec '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20
Capital Expenditures 23.25
3,608.00
4,786.00
2,972.00
4,299.00
4,145.00
3,984.00
5,470.00
5,824.00
growth rate 1,145.9% 32.7% -37.9% 44.7% -3.6% -3.9% 37.3% 6.5%
Cash Dividends 63.55
61.82
8,247.00
8,264.00
9,923.00
10,751.00
10,559.00
10,580.00
10,379.00
growth rate -1.4% 13,241.1% 0.2% 20.1% 8.3% -1.8% 0.2% -1.9%
Cash From OA 156.83
9,942.00
25,958.00
25,386.00
22,525.00
10,843.00
42,843.00
32,894.00
39,947.00
growth rate 696.2% 161.1% -2.2% -11.3% -51.9% 295.1% -23.2% 21.4%
FCF per Share 1.06
0.43
2.46
0.30
0.34
0.43
0.42
-0.11
0.56
0.52
0.60
growth rate -59.4% 472.1% -87.8% 13.3% 26.5% -2.3% -100.0% 100.0% -7.1% 15.4%
FCF 11,849.00
21,483.00
26,110.00
9,942.00
25,958.00
-41,054.00
13,433.00
1,343.00
32,906.00
24,561.00
30,719.00
growth rate 81.3% 21.5% -61.9% 161.1% -100.0% 100.0% -90.0% 2,350.2% -25.4% 25.1%
Income Statement Dec '11 Mar '12 Dec '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20
Sales 835.24
119,066.00
148,663.00
161,831.00
195,291.00
199,096.00
224,942.00
234,026.00
241,555.00
growth rate 1,094.0% 24.9% 8.9% 20.7% 2.0% 13.0% 4.0% 3.2%
Op.Income 195.15
16,520.00
27,315.00
35,240.00
36,330.00
32,904.00
38,802.00
41,390.00
39,860.00
growth rate 820.1% 65.4% 29.0% 3.1% -9.4% 17.9% 6.7% -3.7%
IBT 202.87
186.81
26,892.00
35,863.00
79,470.00
31,822.00
39,261.00
43,117.00
32,091.00
growth rate -4.0% 14,295.0% 33.4% 121.6% -60.0% 23.4% 9.8% -25.6%
Net Income 125.27
16,520.00
17,109.00
24,032.00
53,373.00
23,061.00
35,247.00
31,954.00
23,618.00
growth rate 1,048.4% 3.6% 40.5% 122.1% -56.8% 52.8% -9.3% -26.1%
EPS 118.97
39.35
219.85
39.10
47.63
57.93
128.41
52.76
86.42
78.43
59.01
growth rate -66.9% 458.7% -82.2% 21.8% 21.6% 121.7% -58.9% 63.8% -9.3% -24.8%
Gross Profit 576.93
77,565.00
90,559.00
105,458.00
122,462.00
124,130.00
138,564.00
143,262.00
146,724.00
growth rate 1,059.5% 16.8% 16.5% 16.1% 1.4% 11.6% 3.4% 2.4%
R&D 19,040.00
17,477.00
19,990.00
22,786.00
23,341.00
23,341.00
23,341.00
growth rate -8.2% 14.4% 14.0% 2.4% 0.0% 0.0%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT 9,247.00
9,766.00
9,930.00
10,917.00
8,016.00
growth rate 5.6% 1.7% 9.9% -26.6%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 82,349.00
78,342.00
87,222.00
86,999.00
82,174.00
growth rate -4.9% 11.3% -0.3% -5.6%
Acct.Payable 27,189.00
31,411.00
30,628.00
32,578.00
33,815.00
growth rate 15.5% -2.5% 6.4% 3.8%
Cur.Assets 188,328.00
202,428.00
207,411.00
218,556.00
209,053.00
growth rate 7.5% 2.5% 5.4% -4.4%
Total Assets 386,304.00
397,073.00
407,712.00
408,768.00
409,586.00
growth rate 2.8% 2.7% 0.3% 0.2%
Cash 67,798.00
84,972.00
82,595.00
91,430.00
82,346.00
growth rate 25.3% -2.8% 10.7% -9.9%
Inventory 33,738.00
33,652.00
33,037.00
35,282.00
38,663.00
growth rate -0.3% -1.8% 6.8% 9.6%
Cur.Liabilities 52,812.00
59,583.00
58,954.00
67,597.00
62,337.00
growth rate 12.8% -1.1% 14.7% -7.8%
Liabilities 96,447.00
101,881.00
103,899.00
106,208.00
103,762.00
growth rate 5.6% 2.0% 2.2% -2.3%
LT Debt 1,965.00
growth rate
Equity 288,271.00
293,662.00
302,248.00
302,865.00
306,193.00
growth rate 1.9% 2.9% 0.2% 1.1%
Common Shares 8,283.00
8,287.00
8,296.00
8,366.00
8,411.00
growth rate 0.1% 0.1% 0.8% 0.5%
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 1,182.00
1,610.00
1,861.00
1,171.00
1,330.00
growth rate 36.2% 15.6% -37.1% 13.6%
Cash Dividends 5,102.00
80.00
5,127.00
70.00
5,520.00
growth rate -98.4% 6,308.8% -98.6% 7,785.7%
Cash From OA 4,999.00
18,589.00
3,774.00
12,585.00
7,445.00
growth rate 271.9% -79.7% 233.5% -40.8%
FCF 3,817.00
16,979.00
1,913.00
11,414.00
6,115.00
growth rate 344.8% -88.7% 496.7% -46.4%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 59,136.00
59,639.00
63,551.00
59,229.00
57,563.00
growth rate 0.9% 6.6% -6.8% -2.8%
Op.Income 9,247.00
9,766.00
9,930.00
10,917.00
8,016.00
growth rate 5.6% 1.7% 9.9% -26.6%
IBT 9,002.00
9,405.00
10,555.00
3,127.00
8,359.00
growth rate 4.5% 12.2% -70.4% 167.3%
Net Income 6,399.00
6,749.00
7,152.00
3,317.00
6,189.00
growth rate 5.5% 6.0% -53.6% 86.6%
EPS
growth rate
Gross Profit 35,016.00
35,457.00
37,495.00
38,755.00
32,822.00
growth rate 1.3% 5.8% 3.4% -15.3%
R&D 6,174.00
5,238.00
5,741.00
-17,153.00
5,616.00
growth rate -15.2% 9.6% -100.0% 100.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (48.16)

YOY Growth Grade:

D (40.99)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 20.92 20.92 21.00
EPS / Growth 70.9% 0.77 -6.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 41.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 37.8% 37.8%
Future PE 2.00 20.97 39.20
Future EPS 0.85 18.94 18.94
Value Price
MOS %
0.42
98.20
183.54
MOS Price 0.21 49.10 91.77
IRT

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.